Propanc Biopharma raises $1mln in convertible preferred stock from Hexstone Capital.

Propanc Biopharma has entered into a securities purchase agreement with Hexstone Capital for a private placement of up to $100 million in convertible preferred stock. The funds will be used to support the company's digital asset acquisition strategy and accelerate its R&D pipeline, with a focus on entering a First-In-Human study for PRP in H2 2026. The company received an initial investment of $1 million.